Protocol Ledger

NCT04291703 · Phase II · TERMINATED

STOP-T1D Low-Dose (ATG)

Interventional Phase II clinical trial protocol NCT04291703 sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-01 Enrollment: 2 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04291703
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04291703
Protocol FieldVerified Registry Value
NCT IdentifierNCT04291703
Consolidated Lead SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment2 participants (ACTUAL)
Registered Start Date2023-11-01
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI